Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden

1.50 CME
1.50 CNE
90 MINS
$0 FEE
SAVE
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden

Overview


Release Date
September 15, 2023

Expiration Date
September 15, 2024

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Activity Overview

The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding traditional and recently approved treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), with an eye on providing extended treatment intervals for patients. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with nAMD and DME.

Target Audience

This educational activity is directed toward retina specialists and general ophthalmologists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the limitations of intravitreal anti-vascular endothelial growth factor (VEGF) therapies that are currently used to treat nAMD and DME.
  • Summarize clinical trial data regarding both traditional and emerging agents used for the management of nAMD and DME.
  • Create individualized treatment plans that utilize a treat-and-extend dosing strategy in appropriate patients with nAMD and DME.

Faculty

Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin North Hospital and
Cleveland Clinic South Hospital
Staff Surgeon
Cleveland Clinic Florida
Stuart, FL

Disclosures: Consultant: Alcon, Apellis, Bausch + Lomb, EyePoint, Genentech, Iveric Bio, Regeneron.

Ferhina S. Ali, MD, MPH
Vitreoretinal Physician and Surgeon
Advanced Eye Physicians; Attending Physician,
Vitreous/Retina Service
Assistant Professor of Ophthalmology
New York Medical College
Valhalla, NY

Disclosures: Consultant: AbbVie/Allergan, Apellis, EyePoint, Genentech, Regeneron. Speaker’s Bureau: Apellis, Genentech.

Yasha Modi, MD
Associate Professor of Ophthalmology
Director of Tele-retina
NYU Langone Health
New York, NY

Disclosures: Consultant: Alimera, Alcon, AbbVie/Allergan, Eyepoint Pharmaceuticals, Astellas/Iveric Bio, DORC, Genentech, Thea; Advisory Board: Apellis, Regeneron.

Carl D. Regillo, MD, FACS
Chief, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Retina Surgeon
Philadelphia, PA

Disclosures: Grant/Research Support: Adverum, Allergan, Annexon, Apellis, Astellas, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Opthea, Regeneron, Regenxbio. Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Clearside, Eyepoint, Genentech, Graybug, Iveric, Janssen, Kodiak, Lineage, Merck, NGM, Novartis, Ocugen, Opthea, Regenxbio, Stealth, Thea, Zeiss. Stock/Shareholder: Ocugen.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.